# Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

> **NCT04223635** · EARLY_PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 16 (actual)

## Conditions studied

- Moderate Hepatic Impairment

## Interventions

- **DRUG:** Pexidartinib

## Key facts

- **NCT ID:** NCT04223635
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2020-10-02
- **Final completion:** 2020-10-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223635, "Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04223635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*